Program Schedule

55
Cytomegalovirus Infection in Pregnant Women, Neonates and Immunocompromised: Common Problem with Not So Easy Answers

Thursday, October 9, 2014: 2:00 PM-3:30 PM
Room: The Pennsylvania Convention Center: 113-ABC

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss whether all pregnant women should be screened for CMV and which of these women should be treated
  • describe criteria to determine which neonates and infants with CMV infection warrant treatment and review the treatment options available
  • discuss the diagnosis and management of CMV infections in immunocompromised patients

Target Audience: Vaccinologists, Scientists, Researchers, Public health practitioners, Pharmacists, Nurses, Microbiologists, Members-in-training, Medical students and residents, Lab personnel, Investigators, Infectious diseases physicians, Infectious diseases pediatricians, Infection preventionists, Hospital epidemiologists, Hospital administrators, HIV clinicians, Health care workers, Fellows, Epidemiologists, Clinicians, Academicians

Tracks: Pediatric ID, Epidemiology and Infection Control, Adult ID

Moderator:  Tina Tan, MD, FIDSA, Northwestern University Feinberg School of Medicine

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-14-108-L01-P

Disclosures:

T. Tan, Merck Labs: Grant Investigator and Scientific Advisor, Research grant
Sanofi Pasteur: Consultant, Grant Investigator and Scientific Advisor, Educational grant, Research grant and Speaker honorarium
GSK: Consultant and Scientific Advisor, Consulting fee
Pfizer Wyeth: Scientific Advisor, Consulting fee
Biota: Scientific Advisor, Consulting fee

S. Boppana, None

D. W. Kimberlin, GSK: Grant Investigator and I served as one of dozens of study sites for clinical trials conducted by GSK. All monies went directly to my university and not to me., Grant recipient
Gilead: Grant Investigator and I served as one of dozens of study sites for clinical trials conducted by Gilead. All monies went directly to my university and not to me., Grant recipient

J. A. Englund, Gilead: Consultant and Investigator, Consulting fee and Research support
Chimerix: Investigator, Research support
Roche: Investigator, Research support
GlaxoSmithKline: Consultant, Investigator and Member, DSMB (DataSafety Monitoring Board), Consulting fee, Payment for DSMB participation and Research support
Ansun Biopharma: Investigator, Research support

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek